Skip to main content
SpringerLink
Log in

Complications of Gastroesophageal Reflux Disease

  • Chapter
  • First Online:
Diagnosis and Treatment of Gastroesophageal Reflux Disease

Abstract

Acute esophageal exposure to gastric and/or duodenal refluxate can result in pyrosis and symptomatic gastroesophageal reflux disease (GERD), as well as erosive esophagitis. The pathophysiology underlying GERD and the esophageal response to acute acid exposure, including esophageal defense mechanisms, are discussed elsewhere in this book. Chronic esophageal acid exposure can result in anatomic and structural changes to the esophagus—ranging from benign lesions (peptic stricture), to premalignant lesions (Barrett’s esophagus), to esophageal adenocarcinoma. These esophageal complications of chronic GERD will be discussed in the following chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. ASGE Standards of Practice Committee, Anderson MA, Ben-Menachem T, Gan SI, Appalaneni V, Banerjee S, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc. 2009;70:1060–70.

    Article  PubMed  Google Scholar 

  2. Marks RD, Richter JE. Peptic strictures of the esophagus. Am J Gastroenterol. 1983;88:1160–73.

    Google Scholar 

  3. Marshall JB, Afridi SA, King PD, Barthel JS, Butt JH. Esophageal dilation with polyvinyl (American) dilators over a marked guidewire: practice and safety at one center over a 5-yr period. Am J Gastroenterol. 1996;91:1503–6.

    CAS  PubMed  Google Scholar 

  4. Kochman ML, McClave SA, Boyce HW. The refractory and recurrent esophageal stricture: a definition. Gastrointest Endosc. 2005;62:474–5.

    Article  PubMed  Google Scholar 

  5. Dzeletovic I, Fleischer DE. Self-dilation for resistant, benign esophageal strictures. Am J Gastroenterol. 2010;105:2142–3.

    Article  PubMed  Google Scholar 

  6. El-Serag HB, Lau M. temporal trended in new and recurrent oesophageal strictures in a medicare population. Aliment Pharmacol Ther. 2007;25:1223–9.

    Article  CAS  PubMed  Google Scholar 

  7. Ganz RA, Allen JI, Leon S, Batts KP. Barrett’s esophagus is frequently overdiagnosed in clinic practice: results of the Barrett’s Esophagus Endoscopic Revision (BEER) study. Gastrointest Endosc. 2014;79:565–73.

    Article  PubMed  Google Scholar 

  8. Harrison R, Perry I, Haddadin W, McDonald S, Bryan R, Abrams K, et al. Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol. 2001;102:1154–61.

    Article  Google Scholar 

  9. American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–91.

    Article  PubMed  Google Scholar 

  10. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.

    Article  PubMed  Google Scholar 

  11. Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392–9.

    Article  PubMed  Google Scholar 

  12. Loughney T, Maydonovitch CL, Wong RK. Esophageal manometry and 24-hour pH monitoring in patients with short and long segment Barrett’s esophagus. Am J Gastroenterol. 1998;93:916.

    CAS  PubMed  Google Scholar 

  13. Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalosvki M. Prospective long-term endoscopic and histological follow-up of short segment Barrett’s esophagus: comparison with traditional long-segment Barrett’s esophagus. Am J Gastroenterol. 1997;92:407–13.

    CAS  PubMed  Google Scholar 

  14. Sarosi G, Brown G, Jaiswal K, Feagins LA, Lee E, Crook TW, et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett’s esophagus. Dis Esophagus. 2008;21:43–50.

    CAS  PubMed  Google Scholar 

  15. Quante M, Bhagat G, Abrams JA, Marache F, Good P, Lee MD, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse-model of Barrett-like metaplasia. Cancer Cell. 2012;21:36–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. McQuaid KR, Laine L, Fennerty MB, Souza R, Spechler SJ. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther. 2011;34:146–65.

    Article  CAS  PubMed  Google Scholar 

  17. Huo X, Juergens S, Zhang X, Rezaei D, Yu C, Strauch ED, et al. Deoxycholic acid causes DNA damage while inducing apoptotic resistance through Nf-kB activation in benign Barrett’s epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011;301:G278–86.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Dahms BB, Rothstein FC. Barrett’s esophagus in children: a consequence of chronic gastroesophageal reflux. Gastroenterology. 1984;86:318–23.

    CAS  PubMed  Google Scholar 

  19. Snyder JD, Goldman H. Barrett’s esophagus in children and young adults. Frequent association with mental retardation. Dig Dis Sci. 1990;35:1185–9.

    Article  CAS  PubMed  Google Scholar 

  20. El-Serag HB, Gilger MA, Shub MD. The prevalence of suspected Barrett’s esophagus in children and adolescents: a multicenter endoscopic study. Gastrointest Endosc. 2006;64:671–5.

    Article  PubMed  Google Scholar 

  21. Nguyen DM, El-Serag HB, Shub M, Integlia M, Henderson L, Richardson P, et al. Barrett’s esophagus in children and adolescents without neurodevelopmental or tracheoesophageal abnormalities: a prospective study. Gastrointest Endosc. 2011;73:875–80.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RK, Vasudeva RS, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–7.

    Article  PubMed  Google Scholar 

  23. Crockett SD, Barritt AS 4th, Shaheen NJ. A 52-year-old man with heartburn: should he undergo screening for Barrett’s esophagus? Clin Gastroenterol Hepatol. 2010;5:565–71.

    Article  Google Scholar 

  24. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology. 2002;123:461–7.

    Article  PubMed  Google Scholar 

  25. Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41.

    Article  PubMed  Google Scholar 

  26. Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett’s esophagus. Gastroenterology. 2007;133:403–11.

    Article  PubMed  Google Scholar 

  27. Kramer JR, Fischbach LA, Richardson P, Alsarraj A, Fitzgerald S, Shaib Y, et al. Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett’s esophagus in white men. Clin Gastroenterol Hepatol. 2013;11:373–81.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Kamat P, Wen S, Morris J, Anandasabapathy S. Exploring the association between elevated body mass index and Barrett’s esophagus: a systematic review and meta-analysis. Ann Thorac Surg. 2009;87:655–62.

    Article  PubMed  Google Scholar 

  29. Greer KB, Thompson CL, Brenner L, Bednarchik B, Dawson D, Willis J, et al. Association of insulin and insulin-like growth factors with Barrett’s oesophagus. Gut. 2012;61:665–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Chak A, Ochs-Balcom H, Falk G, Grady WM, Kinnard M, Willis JE, et al. Familiality in Barrett’s esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev. 2006;15:1668–73.

    Article  PubMed  Google Scholar 

  31. Ash S, Vaccaro BJ, Dabney MK, Chung WK, Lightdale CJ, Abrams JA. Comparison of endoscopic and clinical characteristics of patients with familial and sporadic Barrett’s esophagus. Dig Dis Sci. 2011;56:1702–6.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Chak A, Chen Y, Vengoechea J, Canto MI, Elston R, Falk GW, et al. Variation in age at cancer diagnosis in familial versus nonfamilial Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2012;21:376–83.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Verbeek RE, Spittuler LF, Peute A, van Oijen MG, Ten Kate FJ, Vermeijden JR, et al. Familial clustering of Barrett’s esophagus and esophageal adenocarcinoma in a European cohort. Clin Gastroenterol Hepatol. 2014;12:1656–63.

    Article  PubMed  Google Scholar 

  34. Thrift AP, Cook MB, Vaughan TL, Anderson LA, Murray LJ, Whiteman DC, et al. Alcohol and the risk of Barrett’s esophagus: a pooled analysis from the International BEACON Consortium. Am J Gastroenterol. 2014;109:1586–94.

    Article  PubMed  Google Scholar 

  35. Sonnenberg A, Lash RH, Genta RM. A national study of Helicobacter pylori infection in gastric biopsy specimens. Gastroenterology. 2010;139:1894–901.

    Article  PubMed  Google Scholar 

  36. Blaser MJ. Helicobacter pylori and esophageal disease: wake-up call? Gastroenterology. 2012;139:1819–22.

    Article  Google Scholar 

  37. Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137:588–97.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149–58.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Bhat SK, McManus DT, Coleman HG, Johnston BT, Cardwell CR, McMenamin U, et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut. 2015;64:20–5.

    Article  PubMed  Google Scholar 

  40. Sikkema M, de Jonge PJF, Steyewberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–44.

    Article  PubMed  Google Scholar 

  41. Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, Lemmens VE, van Heijningen EB, Aragonés N, et al. Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands. Am J Gastroenterol. 2014;109:336–43.

    Article  CAS  PubMed  Google Scholar 

  42. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003;124:47–56.

    Article  CAS  PubMed  Google Scholar 

  43. Liao LM, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012;142:442–52.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ, Probar-study Group. Nonsteroidal anti-inflammatory drugs and statins have chemopreventive effects in patients with Barrett’s esophagus. Gastroenterology. 2011;141:2000–8.

    Article  CAS  PubMed  Google Scholar 

  45. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology. 2000;119:333–8.

    Article  CAS  PubMed  Google Scholar 

  46. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–57.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Schouten LJ, Steevens J, Huysentruty CJ, Coffeng CE, Keulemans YC, van Leeuwen FE, et al. Total cancer incidence and overall mortality are not increased among patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2011;9:754–61.

    Article  PubMed  Google Scholar 

  48. Hvid-Jensen F, Pedersen L, Drewes Am, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–83.

    Article  CAS  PubMed  Google Scholar 

  49. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67:394–8.

    Article  PubMed  Google Scholar 

  50. Wani S, Falk GW, Post J, Yerian L, Hall M, Wang A, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141:1179–86.

    Article  PubMed  Google Scholar 

  51. Singh S, Manickam P, Amin AV, Samala N, Schouten LJ, Iyer PG, et al. Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79:897–909.

    Article  PubMed  Google Scholar 

  52. Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–30.

    Article  PubMed  Google Scholar 

  53. Duits LC, Phoa KN, Curvers WL, Ten Kate FJ, Meijer GA, Seldenrijk CA, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64:700–6.

    Google Scholar 

  54. Chatelain D, Flejou JF. High-grade dysplasia and superficial adenocarcinoma in Barrett’s esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins. Virchows Arch. 2003;442:18–24.

    CAS  PubMed  Google Scholar 

  55. Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. Variable pathologic interpretation of columnar-lined esophagus by general pathologists in community practice. Gastrointest Endosc. 1999;50:23–6.

    Article  CAS  PubMed  Google Scholar 

  56. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance of Barrett’s esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138:176–86.

    Article  PubMed  Google Scholar 

  57. Soni A, Sampliner RE, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective? Am J Gastroenterol. 2000;95:2086–93.

    Article  CAS  PubMed  Google Scholar 

  58. Rubenstein JH, Scheiman JM, Sadeghi S, Whiteman D, Inadomi JM. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol. 2011;106:254–60.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Chak A, Alashkar BM, Isenberg GA, Chandar AK, Greer KB, Hepner A, et al. Comparative acceptability of transnasal esophagoscopy and esophageal capsule esophagoscopy: a randomized, controlled trial in veterans. Gastrointest Endosc. 2014;80:774–82.

    Article  PubMed  Google Scholar 

  60. Kadri SR, Lao-Sirieix P, O’Donovan M, Debiram I, Das M, Blazeby JM, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. Br Med J. 2010;341:c4372. doi:10.1136/bmj.c4372.

    Article  Google Scholar 

  61. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett’s esophagus. Am J Gastroenterol. 1994;89:670–80.

    CAS  PubMed  Google Scholar 

  62. Provenzale D, Schmitt C, Wong JB. Barrett’s esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2043–53.

    Article  CAS  PubMed  Google Scholar 

  63. Corley DA, Methani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145:312–9.

    Article  PubMed Central  PubMed  Google Scholar 

  64. Verbeek RE, Leenders M, Ten Kate FJ, van Hillegersberg R, Vleggaar FP, van Baal JW, et al. Surveillance of Barrett’s esophagus and mortality from esophgageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol. 2014;109:1215–22.

    Article  PubMed  Google Scholar 

  65. Ngamruenqphong S, Wolfsen HC, Wallace MB. Survival of patients with superficial esophageal adenocarcinoma after endoscopic treatment vs surgery. Clin Gastroenterol Hepatol. 2013;11:1424–9.

    Article  Google Scholar 

  66. Dunbar KB, Spechler SJ. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett’s esophagus: a systematic review. Am J Gastroenterol. 2012;107:850–62.

    Article  PubMed Central  PubMed  Google Scholar 

  67. Prasad GA, Buttar NS, Wongkeesong LM, Lewis JT, Sanderson SO, Lutzke LS, et al. Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett’s esophagus. Am J Gastroenterol. 2007;102:2380–6.

    Article  PubMed Central  PubMed  Google Scholar 

  68. Ayers K, Shi C, Washington K, Yachimski P. Expert pathology review and endoscopic mucosal resection alters the diagnosis of patients referred to undergo therapy for Barrett’s esophagus. Surg Endosc. 2013;27:2836–40.

    Article  PubMed  Google Scholar 

  69. Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, et al. Long-term results and risk factor analysis for recurrence after curative endosocopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57:1200–6.

    Article  CAS  PubMed  Google Scholar 

  70. Konda VJ, Gonzalez Haba Ruiz M, Koons A, Hart J, Xiao SY, Siddiqui UD, et al. Complete endoscopic mucosal resection is effective and durable treatment for Barrett’s-associated neoplasia. Clin Gastroenterol Hepatol. 2014;12:2002–10.

    Article  PubMed  Google Scholar 

  71. Overholt BF, Wang KK, Burdick JS, Lightdale CJ, Kimmey M, Nava HR, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett’s high-grade dysplasia. Gastrointest Endosc. 2007;66:460–8.

    Article  PubMed  Google Scholar 

  72. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–88.

    Article  CAS  PubMed  Google Scholar 

  73. Pech O, May A, Manner H, Behrens A, Pohl J, Weferling M, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology. 2014;146;652–60.

    Article  PubMed  Google Scholar 

  74. Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett’s esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;31:1209–17.

    Article  Google Scholar 

  75. El-Serag HB, Graham DY. Routine polypectomy for colorectal polyps and ablation for Barrett’s esophagus are intellectually the same. Gastroenterology. 2011;140:386–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, 1660 The Vanderbilt Clinic, 37232-5280, Nashville, TN, USA

    Patrick Yachimski MD, MPH

Authors
  1. Patrick Yachimski MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Yachimski MD, MPH .

Editor information

Editors and Affiliations

  1. Department of Gastroenterology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

    Michael F. Vaezi

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Yachimski, P. (2016). Complications of Gastroesophageal Reflux Disease. In: Vaezi, M. (eds) Diagnosis and Treatment of Gastroesophageal Reflux Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-19524-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19524-7_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19523-0

  • Online ISBN: 978-3-319-19524-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation